Ginkgo Bioworks Stock

ginkgobioworks.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $785.53MM

Ginkgo Bioworks is the developer of a cell programming platform enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Register To Buy and Sell Shares

For more details on financing and valuation for Ginkgo Bioworks, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Ginkgo Bioworks’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Ginkgo Bioworks.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Barry Canton
Co-Founder
Peter Boynton
Chief Commercial Officer
Austin Che
Co-Founder
Ena Cratsenburg
Chief Business Officer
Jason Kelly
Co-Founder, Chief Executive Officer & Board Member
Reshma Shetty
Co-Founder, President & Board Member
Tom Knight
Co-Founder

Board Members

Marjin Dekkers
Christian Henry

News Highlights

Ginkgo Bioworks to Acquire Swiss Bioengineering Firm FGen
FGen, a spinout of ETH Zurich, is a contract research organization specializing in strain development and optimization.
Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm
Project Beacon COVID-19 was started by F-Prime Capital, GV, and the Broad Institute to help implement COVID-19 testing in Massachusetts and its environs.
FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Today’s Important Deadline in Securities Class Action Commenced by the Firm – DNA, SRNG
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo...
Updated on: Apr 13, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.